In Victoria, Australian health officials are proposing to restrict permits currently allowing patients with mental illnesses to access psychedelics in a therapeutic framework back to research and clinical trials “approved by a human research ethics committee.”
At the moment, psychiatrists are allowed to apply for prescribing MDMA and psilocybin nationally through the Therapeutic Goods Administration (TGA) and the health department for patients who do not respond to other available treatments.
